Clarivate Plc

Clarivate Plc engages in the provision of global information, analytics and workflow solutions. It operates through the Science and Intellectual Property segments. The Science segment is composed of the academia and government, and life science and healthcare product lines. The Intellectual Property segment includes the patent, trademark, domain, and IP management product lines. The company was founded in 1864 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Clarivate Plc reports strong Q4 earnings, eyes growth opportunities

Clarivate Plc delivered strong financial results in Q4 2022, driven by the successful ProQuest acquisition and solid organic growth across segments. The company is focused on achieving higher organic growth, reducing leverage, and leveraging culture for success.
While facing macroeconomic challenges and pricing pressures, Clarivate Plc is confident in its strategic plans and capital structure initiatives. Opportunities lie in leveraging AI, enhancing product offerings, and capitalizing on the positive pricing environment.
Navigating challenges such as tough comps, managing inflation impact, and balancing quarterly patterns will be crucial. The company's proactive approach to growth, focus on customer value, and upcoming Investor Day position it well for future success.

Clarivate Plc reports stable Q1 performance amidst growth challenges

Clarivate Plc's Q1 2023 performance showcased stable revenue, strong margins, and strategic financial initiatives despite challenges in net income and organic growth cadence.
The company's strengths lie in market engagement, AI innovation, maintained outlook, and effective pricing strategies, positioning it for continued growth.
Challenges include earnings volatility, execution hurdles in growth projections, and longer-term segment revenue impacts, necessitating strategic planning and operational focus.
Opportunities in AI applications, cash flow utilization, revenue drivers, and segment progress offer avenues for revenue diversification, growth investments, and market expansion.

Clarivate Plc faces revenue challenges but drives growth through innovation

Clarivate Plc's Q2 performance saw challenges in key segments impacting revenue and outlook, despite operational improvements and strategic initiatives.
While facing hurdles in patent annuities and commercialization subsegment growth, the company focuses on sustainability, product innovations, and customer-centric strategies for future growth.
Detailed financial results and revised guidance reflect the company's proactive approach to address challenges and capitalize on opportunities for sustainable growth.
With a pivot around three segments and emphasis on higher-touch sales, Clarivate aims to navigate challenges, leverage opportunities, and drive revenue growth in the evolving market landscape.

Clarivate Plc reports Q3 growth, tackles challenges, eyes tech acquisitions

Clarivate Plc's Q3 performance showed growth in key segments despite challenges in IP and LS&H businesses.
Opportunities lie in technology acquisitions, analytic platforms, and direct sales to pharma companies.
Management remains optimistic about quarterly results and progress, focusing on enhancing growth strategies.

Clarivate Plc reports solid Q4 performance amidst sector challenges

Clarivate Plc's Q4 2023 performance reflects progress in key segments and a strategic focus on organic growth and operational efficiencies.
While facing challenges in the A&G segment and market conservatism, the company is leveraging strengths in Life Sciences investments and pricing strategies.
Opportunities lie in growth acceleration through new offerings, improved organic growth, and renewed optimism in the life sciences sector.

Clarivate Plc reports Q1 revenue growth, eyes segment expansion

Clarivate Plc's Q1 performance showed promising organic revenue growth and steady renewal rates, with a focus on future investments for growth.
While facing financial challenges and neutral market conditions, the company sees opportunities in segment growth and real-world data solutions.
Overall, Clarivate remains on track with full-year guidance, aiming for 1% organic growth and focusing on driving subscription business growth.

Clarivate Plc reports mixed Q2 results, focuses on growth strategies

Clarivate Plc reported mixed financial results in Q2 2024, with slight revenue growth but challenges in certain segments.
Management emphasized resilience in adjusted EPS and operating cash flow, focusing on growth plans and operational improvements.
Analysts raised concerns about project delays and segment performance, but opportunities in product innovation and revenue growth were highlighted.
The company aims to drive subscription revenue growth through upcoming product releases and investment in business.

Clarivate Plc faces revenue decline in Q3 but focuses on growth strategies

Clarivate Plc's Q3 2024 earnings call highlighted challenges in revenue decline and net loss, with a focus on repositioning and value creation. The company is implementing a Value Creation Plan to optimize its business model and drive sustainable growth. Opportunities exist in improving sales execution, product innovation, and aligning the portfolio for enhanced profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clarivate Plc engages in the provision of global information, analytics, and workflow solutions. It operates through the following segments: Academia and Government (A&G), Intellectual Property (IP), and Life Sciences and Healthcare (LS&H). The A&G segment involves the provision of research and analytics, content aggregation, and workflow software solutions using artificial intelligence. The IP segment includes the maintenance, intelligence, and management solutions. The LS&H focuses on solutions for research and development, regulatory and safety, and commercialization. The company was founded in 1864 and is headquartered in London, the United Kingdom.

— Provides 2023 Outlook — LONDON , March 1, 2023 /PRNewswire/ -- Clarivate Plc - (NYSE: CLVT) (the "Company" or "Clarivate"), a global leader in connecting people and organizations to intelligence they can trust, today reported results for the fourth quarter and full year ended December 31, 2022. Fourth  Quarter 2022 Financial Highlights Revenues of $675.3 million increased 20.4%, and 25.2% at constant currency(1), driven primarily by the acquisition of ProQuest Organic revenues(1) increased 0.5% as increases in subscription revenues of 2.5% and re-occurring revenues of 2.5% were partially offset by a decline in transactional and other revenues of 5.9% Net income attributable to ordinary shares was $304.3 million compared to Net loss attributable to ordinary shares of $130.4 million in the prior year quarter driven by the gain from the MarkMonitor divestiture; Net income per diluted share of $0.44 increased by $0.64 Adjusted Net Income(1) of $164.0 million increased 0.5%; Adjusted Income per diluted share(1) of $0.22 decreased 4.3% or $0.01 Adjusted EBITDA(1) of $304.4 million increased 18.6% driven by earnings contributions from acquisitions, organic growth and cost savings from integration programs; Adjusted EBITDA Margin(1) of 45.1% decreased 70 basis points Full Year 2022 Financial Highlights Revenues of $2,659.8 million increased 41.7%, and 46.9% at constant currency(1), driven primarily by the acquisition of ProQuest Organic revenues(1) increased 2.6% as increases in subscription revenues of 3.4% and re-occurring revenues of 5.2% were partially offset by a decline in transactional and other revenues of 2.7% Net loss attributable to ordinary shares of $4,035.6 million increased $3,723.6 million due to the $4,449.1 million non-cash impairment of goodwill; Net loss per diluted share of $6.24 increased by $5.63 Adjusted Net Income(1) of $628.0 million increased 30.4%; Adjusted Income per diluted share(1) of $0.85 increased 18.1% or $0.13 Adjusted EBITDA(1) of $1,112.7 million increased 39.0% and Adjusted EBITDA Margin(1) of 41.8% decreased 80 basis points Cash Flows from Operations increased $185.5 million to $509.3 million; Adjusted Free Cash Flow(1) increased $62.4 million to $521.8 million "2022 was a pivotal year for Clarivate as we made progress on many fronts and transitioned the company for future achievements," said Jonathan Gear, Chief Executive Officer.

Clarivate Reports Fourth Quarter and Full Year 2022 Results

—Clarivate will ring the opening bell at the New York Stock Exchange on March 6 — LONDON , Feb. 23, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, announced today details for its upcoming Investor Day conference on Thursday, March 9, 2023 in New York. Due to limited capacity, in-person attendance is by invitation only.

Clarivate Announces Details of its Investor Day on March 9, 2023

Providing key insights for building a sustainable industry ecosystem LONDON , Feb. 22, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform the world, and the KAIST Innovation Strategy and Policy Institute (ISPI), a top research institution in South Korea today launched a collaborative report on the global innovation landscape of the artificial intelligence (AI) chip industry. The report suggests it is crucial to build an innovation ecosystem to stimulate mutual-cooperation among universities, enterprises and government-funded research institutes.

Clarivate and KAIST Innovation Strategy and Policy Institute Release Report on the Global AI Chip Innovation Landscape

New report identifies consistent above-the-bar innovation performance, and reveals top 50 most cited research organizations from the Top 100 by blending insights on inventive activity and scientific discovery LONDON , Feb. 16, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today revealed its 2023 list of Top 100 Global Innovators™ – companies and organizations which sit at the very top of the global innovation ecosystem, with the most consistent above-the-bar innovation performance. New this year: The report marries insights from Clarivate on inventive activity and scientific discovery to better track the flow of modern innovation - to identify the 50 research organizations most often cited by the Top 100 Global Innovators 2023.

Clarivate Names Top 100 Global Innovators 2023

Clarivate PLC (CLVT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Clarivate PLC (CLVT) Upgraded to Strong Buy: Here's What You Should Know

Ares Capital

Deutsche Telekom AG

Haemonetics

 StoneX Group

SNEX, DTEGY, CLVT, HAE and ARCC have been added to the Zacks Rank #1 (Strong Buy) List on February 10, 2022.

New Strong Buy Stocks for February 10th

Helping researchers more easily access preprints within trusted platform to advance scientific progress LONDON , Feb. 9, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, has added the Preprint Citation Index™ to the Web of Science™ platform. Researchers can now locate and link to preprints alongside other trusted content in the database, to streamline the research process and help make meaningful connections faster.

Clarivate Adds Preprint Citation Index to the Web of Science

Here is how Clarivate PLC (CLVT) and Lyft (LYFT) have performed compared to their sector so far this year.

Is Clarivate (CLVT) Outperforming Other Computer and Technology Stocks This Year?

LONDON , Feb. 7, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, announced today it will report its financial results for the fourth quarter and full year 2022 before the market opens on Wednesday, March 1. The press release and earnings supplement, with accompanying financial information, will be posted on the Clarivate investor website at https://ir.clarivate.com.

Clarivate to Report Fourth Quarter and Full Year 2022 Results on March 1, 2023

In-depth analysis of obesity highlights latest advances in weight loss drugs, the search for biological fitness mediators and the pros and cons of weight as a proxy for health LONDON , Feb. 6, 2023 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, explores how difficult scientific detachment can be for health topics that have large cultural components- such as obesity. After many years of research and development, drug-induced weight loss has matured into a viable therapeutic option.

BioWorld by Clarivate Rethinks Obesity in New Special Investigation, Finding Fitness May Be More Linked to Health than Weight

Advanced Micro Devices

Safe Bulkers

Targa Resources

These three stocks have seen stellar EPS growth over the last five years and their attractive valuations make them appear to have more short-term upside in addition to being solid long-term investments.

Time to Buy these Top-Rated Growth Stocks at a Discount?

Clarivate has a very attractive business model in an industry with positive trends. CLVT should be able to continue exerting its pricing power to drive organic growth.

Clarivate: Attractive Business Model With Improving Organic Growth

Expedia

Clarivate Plc (CLVT), Expedia Group (EXPE) and Haemonetics Corporation (HAE) are three stocks with explosive relative price strength.

Time To Pick These 3 Top Relative Price Strength Stocks

AMN Healthcare Services

Core & Main

CRH PLC

Deere & Company

The stock market gains momentum as consumer sentiment improves on fading inflation. Thus, invest in growth players like AMN Healthcare Services (AMN), Clarivate (CLVT), Core & Main (CNM), CRH & Deere (DE) for solid returns.

Wall Street Books Best Week Since November: 5 Growth Picks

The mean of analysts' price targets for Clarivate PLC (CLVT) points to a 39.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Clarivate PLC (CLVT)? Wall Street Analysts Think 39.2%

Report highlights personalized medicines ensuring greater efficacy for rare diseases and previously untreatable conditions Promising therapeutic developments for HIV, Parkinson's disease, Crohn's disease, alopecia, multiple myeloma and breast cancer on horizon LONDON , Jan. 10, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of its annual Drugs to Watch™ report. In its 10th year, the Drugs to Watch report provides in-depth predictive analysis of drugs with the potential to transform treatment paradigms and serve unmet patient needs.

Clarivate Identifies Fifteen Potential Blockbuster Drugs in Annual Drugs to Watch Report

Selecting significant research specialties in sciences and social sciences LONDON , Jan. 3, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, and the Chinese Academy of Sciences (CAS) today released  Research Fronts 2022 , their ninth annual collaborative report. The report identifies significant areas in the world of sciences and social sciences as to where the scientific community is focusing its attention, including several COVID-related fronts and areas mirrored by the research fields of Noble Prize in recent years.

Clarivate and the Chinese Academy of Sciences Release Annual Joint Report to Identify 165 Research Fronts

LONDON , Dec. 22, 2022 /PRNewswire/ -- ClarivatePlc (NYSE: CLVT) today announced that its Board of Directors adopted a tax benefits preservation plan (the "Tax Benefits Preservation Plan") designed to protect the availability of Clarivate's U.S. net operating loss carryforwards ("NOLs") and certain other U.S. tax attributes, which can be utilized in certain circumstances to offset future U.S. tax liabilities. As of September 30, 2022, Clarivate estimates that it had U.S. federal net operating loss and interest carryforwards in excess of $1.0 billion.

CLARIVATE ADOPTS TAX BENEFITS PRESERVATION PLAN TO PROTECT AVAILABILITY OF NET OPERATING LOSSES

LONDON , Dec. 20, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) today announced that, to further enhance the Company's governance profile, it has decreased the size of its Board of Directors from 14 to 11 members. Three directors, Balakrishnan S.

CLARIVATE REDUCES BOARD SIZE, ENHANCING CORPORATE GOVERNANCE

LONDON , Dec. 6, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the inclusion of linked specialty pharmacy claims data within real world data solutions. The new U.S. dataset will expand the real world data and analytics offerings from Clarivate.

Clarivate Expands Real World Data and Analytics Solutions with Addition of U.S. Specialty Pharmacy Data

LONDON , Dec. 1, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced today that Jonathan Gear, Chief Executive Officer, and Jonathan Collins, Executive Vice President and Chief Financial Officer, will present at the Barclays Global Technology, Media and Telecommunications Conference on Wednesday, December 7, 2022 at 10:25 am Pacific Time (1:25 pm Eastern Time). The live webcast can be accessed at https://event.webcasts.com/starthere.jsp?ei=1585417&tp_key=08649f5cce&tp_special=8 and will be available for replay.

Clarivate to Present at the Barclays Global Technology, Media and Telecommunications Conference on December 7

LONDON , Nov. 17, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today launched its annual report which examines the research performance of each of the members of the G20 with a visual comparative snapshot for each. The report, The Annual G20 Scorecard – Research Performance 2022 , has been created by the Institute for Scientific Information™ at Clarivate to coincide with this year's G20 Summit hosted by Bali.

Clarivate Annual G20 Scorecard Report Reveals Insights into World's Leading Research Economies

Investors need to pay close attention to Clarivate (CLVT) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Clarivate (CLVT) Stock?

Partnership to lead the digital transformation of intellectual property and intangible assets by leveraging Clarivate data to power IPwe's Smart Intangible Asset Management platform LONDON , Nov. 16, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced a strategic partnership with IPwe Inc., a leader in blockchain technology that provides smart solutions for the management of intangible assets through data-driven recommendations. The vision of this partnership is to enable Clarivate and IPwe customers to accelerate innovation through accessing uniquely curated patent data from Clarivate within IPwe's artificial intelligence (AI), predictive analytics, and blockchain technology platform.

Clarivate Partners with IPwe to Enhance AI and Blockchain Patent Solutions

Institute for Scientific Information deepens qualitative analysis of annual list to improve detection of gaming, misconduct LONDON , Nov. 15, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today revealed its 2022 list of Highly Cited Researchers™ – individuals at universities, research institutes and commercial organizations who have demonstrated a disproportionate level of significant and broad influence in their field or fields of research. The methodology draws on data from the Web of Science™ citation index, together with analysis performed by bibliometric experts and data scientists at the Institute for Scientific Information (ISI)™ at Clarivate.

News for Clarivate Plc Stock (CLVT)